Page 76 - Let them speak Towards a patient reported outcome measure set for
P. 76
Chapter 3
Regulatory Decision Making. https://www.fda.gov/drugs/development-approval-process-
drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-
patients-voice-medical2023.
61. Agency EM. Patient experience data in medicines development and regulatory decision-making.
https://www.ema.europa.eu/en/events/multi-stakeholder-workshop-patient-experience-data-
medicines-development-regulatory-decision-making#documents-section2022.
62. Compendium P. Guide To Patient Involvement In Rare Disease Therapy Development. https://
everylifefoundation.org/wp-content/uploads/2022/01/Guide-to-Patient-Involvement-FINAL-
COMPLETE-GUIDE-Rev.pdf2022.
63. Administration USFaD. Rare diseases: common issues in drug development: guidance for
industry (draft guidance). Washington, D.C.: US FDA2015.
64. Nicolaidis C, Raymaker DM, McDonald KE, Lund EM, Leotti S, Kapp SK, et al. Creating accessible
survey instruments for use with autistic adults and people with intellectual disability: Lessons
learned and recommendations. Autism in Adulthood. 2020;2(1):61-76.
65. Mokkink L, Terwee C, de Vet H. Key concepts in clinical epidemiology: Responsiveness, the
longitudinal aspect of validity. Journal of clinical epidemiology. 2021;140:159-62.
74
